Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center retrospective cohort study from Jinling Hospital in Nanjing that compares survival outcomes between patients treated with surgery (alone, or with neoadjuvant or adjuvant therapy) and those treated with definitive non-surgical, chemoradiotherapy–based regimens for limited-stage disease. Researchers will collect baseline clinical and pathological data, treatment details, and follow-up information to analyze survival differences. The goal is to clarify whether surgical management contributes to better outcomes in this rare, aggressive cancer. Being observational, the study can suggest associations but cannot establish causation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients pathologically diagnosed with primary small cell esophageal carcinoma (SCEC).
* Patients classified as having limited-stage disease at initial diagnosis, defined as tumor confined to the esophagus and/or regional lymph nodes without evidence of distant metastasis.
* Patients who received definitive treatment at the study institution, including surgical treatment (with or without neoadjuvant or adjuvant therapy) or definitive non-surgical treatment such as chemoradiotherapy-based therapy.
* Patients with complete baseline clinicopathological and treatment information available in the medical records.
* Patients with available follow-up and survival outcome data.

Exclusion Criteria:

* Patients with extensive-stage disease or distant metastasis at diagnosis.
* Patients with mixed histological subtypes in which small cell carcinoma was not the predominant component.
* Patients who received palliative treatment only.
* Patients with a history of other active malignant tumors within the previous 5 years.
* Patients with incomplete key clinical, treatment, or follow-up data.
* Patients under 18 years old.

Where it's running

• Jinling Hospital, Nanjing, Jiangsu Province, China.
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Yi Shen, MD
• Email: dryishen@nju.edu.cn
• Phone: +8613913907880

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Postoperative Low Oxygen and Chance of Leaks After Esophageal Surgery

  This study looks at whether low oxygen levels after esophageal cancer surgery increase the chance of an anastomotic leak.

  Recruiting at 6 sites Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07309991

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Indocyanine green to highlight tumor depth and margins during endoscopic removal of esophageal or stomach cancer

  This trial will test whether a dye called indocyanine green can help doctors see the depth and edges of superficial esophageal or stomach cancers during endoscopic submucosal dissection.

  Recruiting Phase 1/2 University Medical Center Groningen · Groningen, Provincie Groningen · NCT07108855

• Best time for minimally invasive local treatment after first-line systemic therapy for limited (oligo) esophageal or stomach cancer

  This trial will test whether giving local treatment (surgery or radiation) earlier or later after first-line systemic therapy works better for people whose esophageal or stomach cancer has spread to only a few sites.

  Recruiting at 4 sites Phase 2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam and 4 other locations · NCT07000253

• Vanguard: a new blood test approach to screen for multiple cancers

  This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.

  Recruiting at 46 sites National Cancer Institute (NCI) · Pleasanton, California and 45 other locations · NCT06995898

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.